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Giant cell tumor (GCT) is a benign neoplasia in 
the majority of cases, and accounts for around 5% 
of primary bone tumors. It is generally located in 
the epiphysis and metaphysis of the long bones. In 
a large number of cases, it extends close to the arti-
cular cortex, and its occurrence in the bones of the 
hand is rare. GCT occurs more frequently in the third 
and fourth decades of life, with a slight prevalence 
in women(1).
Clinically, its behavior is locally aggressive(1) and 
the main complaint is pain, followed by increased 
limb size and functional impairment(2). In rare cases, 
pulmonary metastasis occurs(1).
The diagnosis is established through clinical correla-
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This is a case report on a giant cell tumor (GCT) in the 
proximal phalanx of the third finger of the left hand, with 
pulmonary metastasis. The patient presented pain in the 
finger without any previous history of trauma. Clinical 
examination, radiographic imaging and magnetic resonance 
imaging were carried out. A histological evaluation was 
carried out from an incisional biopsy, taking the hypothesis 
of GCT. The patient underwent amputation of the finger and 
the diagnosis was confirmed by means of microscopy on 
the specimen. The patient was followed up because of the 
risk of lung metastasis, which was shown by radiographic 
examination and computed tomography on the chest, and 
thoracotomy was performed. Since then, there has been 
an improvement in the symptoms that had been reported 
preoperatively, and no local recurrence or new metastasis 
has been found.
Keywords – Giant cell tumors/surgery; Finger Phalanges; 
Amputation; Neoplasm Metastasis
tion, imaging exams and histopathological data to rule 
out other lesions with a similar histological pattern(1).
The treatment is surgical with a recurrence rate of 
around 5% to 10%(1).
The objective of this work is to report on a case 
of GCT in the proximal phalanx of the third finger of 
the left hand, which evolved to pulmonary metastasis.
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Female patient, aged 25 years, with a history of 
pain in the proximal phalanx of the third finger of 
the left hand, lasting for about one month. She re-
ported an increase in local volume, paresis and limi-
ted movements (flexion and extension) of the finger. 
She reported no trauma or comorbidities. She was 
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./0123$4$5$Hypertransparency in the proximal phalanx of the 
third finger.
./0123$6$5$Evolution of the lesion in one month.
./0123$7$5$Amputation of the third finger, transposing the index 
finger to the resection site.
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not taking any regular medication. On examination, 
there was pain on palpation in the proximal phalanx 
and metacarpophalangeal joint, and limited flexion 
and extension of the third finger.
The x-ray performed in May 2007 showed hyper-
transparency with increased bone volume (Figure 1).
After one month, the lesion showed significant 
growth (Figure 2).
imaging (MRI) showed a large expansive lesion in 
the two proximal thirds of the phalanx of the third 
finger of the left hand, with destructive appearance 
and clear margins, measuring at its widest points: 27.0 
x 24.0 x 24.0 mm. Characterized by hyposignal in T1 
and hypersignal in T2, containing areas with cystic 
appearance in the center. The adjacent extensor tendons 
and other bone and joint structures were preserved. 
At the end of July 2007, the patient was submitted to 
amputation of the third finger, transposing the index 
finger to the resection site (Figure 3).
The piece was sent for anatomapathological study, 
which confirmed the diagnosis of GCT. Macroscopic 
examination of the surgical piece revealed a whitish, 
elastic tumoration with extensive areas of hemorrha-
ge, measuring 2.0 cm at its widest diameter to 5.0 cm 
from the proximal margin of the sample. The lesion 
presented impairment of the proximal phalanx, with 
destruction of the cortex and bone marrow, and inva-
sion to the surrounding soft tissues. Microscopically, 
characteristics of incisional biopsy were apparent, 
with the presence of angiolymphatic tumor invasion, 
but without evidence of malignant sarcomatous trans-
formation. Surgical margins free (Figure 4).
In August 2007, the patient underwent full-body 
bone scintigraphy revealing hyperemia and inflam-
mation of the soft tissues of the left hand, compatible 
with non-specific post-surgical alterations, secondary 
to exeresis of the GCT. The scintigraphic pattern was 
not compatible with additional lesions of the under-
In July 2007, incisional biopsy was performed, 
with histological findings suggestive of GCT of the 
bone, extending to the pariphalangeal soft tissues: 
histological sections of mesenchymal lesion consisting 
of proliferation of osteoclast-type giant cells, 
uniformly distributed with the mononucleated cells 
lacking atypia, with the presence of mitotic activity. 
In the same month, nuclear magnetic resonance 
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./0123$ 8$ 5$Microscopy of the giant cell tumor affecting the 
proximal phalanx.
./0123$9$5$Multislice computed tomography of the thorax with 
metastasis in the left lung.
./0123$:$5$Pulmonary metastasis of intraparenchymal giant cell 
tumor of the bone.
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lying pathology in the other skeletal segments (absen-
ce of multicentric GCT).
In the postoperative evolution, the patient conti-
nued to have free movements in the left hand, without 
complaints, and showed improvement with physio-
therapy. During postoperative follow-up, a semestral 
radiological study was carried out which, 11 months 
after excision of the lesion, showed nodular forma-
tions in both lungs, one in the right middle/upper third 
(around 5.0 mm) and the other in the left lower third 
(around 14.0 mm). Multislice computed tomography 
of the thorax was performed, showing three nodular 
images in pulmonary parenchyma with density of the 
soft tissues, one located in the anterior segment of 
the right upper lobe (6.0 mm) and two located in the 
posterior basal segment of the left lower lobe (15.0 
and 4.0 mm) (Figure 5).
In July 2008, the patient was submitted to explo-
ratory thoracotomy of the left lung, and in the follo-
wing month, the same procedure was carried out in 
the right lung. Exeresis was performed of the four 
nodules on the left and six nodules on the right, all 
benign pulmonary metastasic GCT, without high de-
gree transformation, as confirmed in the anatomopa-
thological tests (Figure 6). The patient evolved well, 
without complaints, and is in tomographic control 
without evidence of local recurrence or metastasis 
in the lungs. She has resumed her normal activities 
and continues in follow-up: every three months in the 
first year, every six months up to five years after the 
treatment, and then annually after this period.
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GCT of the bone is a benign neoplasia, locally 
aggressive, with uncertain biological behavior(1,3,4). 
Approximately 5% to 10% of patients present malig-
nant evolution(1).
GCT represents 5% to 8% of all primary bone tu-
mors, and 20% of all benign bone tumors(1,3-7). Some 
studies show a slight prevalence in women compared 
to men (ratio of 1.3:1)(1,4,5), and a prevalence in the 
third and fourth decades of life(3,7,8). The lesion is rarely 
found before fusion of the epiphyseal plate(3,7).
Location
Its usual location is in the epiphysis of the long 
bones in isolated form; the distal end of the femur and 
proximal end of the tibia correspond to 45-55% of the 
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cases. Other locations include: the distal portion of the 
radius (10-12%), sacrum (4-9%), proximal humerus 
(4-8%), proximal femur (4%) and less frequently in 
the vertebral bodies (2.5%) and bones of the hands 
and feet(1,7).
The condition is rare in the bones of the hand
(2-4%)(2,3,7,9,10). Out of 1547 cases of GCT of the bone 
collected in various studies, only 70 were located in 
the hands or feet(11). It affects patients 10 years young-
er than the average age (32 years) for GCT occurring 
in other locations(11), with more aggressive behavior(9) 
and earlier recurrence(2). The most common locations 
are the metaphyseal region of the metacarpals and 
phalanges. The tumor grows in the direction of the 
diaphysis, which complicates the treatment(10).
Clinical aspects
The majority of patients with GCT are oligosymp-
tomatic with localized pain, with insidious onset and 
progressive deterioration(1,4). The disease evolves with 
increased volume and functional incapacity of the limb, 
particularly if the lesion is near the joint(2,3). However, 
there may be acute pain as a result of pathological frac-
ture(3,7,9). In some cases, the tumor grows quickly, with 
thinning and rupture of the bone cortex and invasion 
of the adjacent soft tissues, but without invading and 
ulcerating the skin and subcutaneous cell tissue(10,11). 
In the hand, the clinical aspect has peculiar characte-
ristics. Pain and swelling occur sooner than in GCT in 
other locations, due to the fact that the tumor is close 
to the surface, and the high mobility of the fingers(11).
Image
The classical radiographic aspects of GCT of the 
bone define it as an eccentric, swollen, lytic epiphy-
seal-metaphyseal lesion, not always with clearly-de-
fined margin(3,4,7,9). Its appearance is radiotransparent, 
with thinning of the cortical bone and absence of in-
ternal calcifications, marginal sclerosis, or periosteal 
reaction. However, there is no pathognomonic cha-
racteristic(9). Although computed tomography (CT) is 
of little use in the differential diagnosis, it confirms 
the absence of calcified matrix, shows the margins of 
the lesion, and reveals the extent of subcortical bone 
loss prior to surgical reconstruction(1). MRI is also 
used in the preoperative evaluation(1). This is consi-
dered the best method for delineating intraosseous, 
extraosseous and intra-articular tumors(1,7). Its greatest 
utility is for demonstrating recurrence of the tumor(1). 
In relation to skeletal screening by bone scintigra-
phy, GCT presents local hypercaptation due to the 
increased reactive osteoblastic activity, with broad 
concentration of the radioindicator in the lesion. In 
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photopenia is present. The exam should be carried out 
to search for other bone lesions(12,13).
The radiological classification of GCT of the bone 
was described by Enneking, and subsequently by Cam-
panacci. There are three stages that correlate the local 
tumor according to its aggressiveness and risk of local 
recurrence(7,8). Stage 1 is the less common. The tumor 
is small and the cortical layer is preserved. There is no 
extension to the joint cartilage. Symptoms are absent 
or minimal. Stage 2 corresponds to 75% of the GCT 
in its initial presentation. The tumor has extended to 
the cortex, which is deformed by the expansion of the 
tumor. There is no extension to the adjacent soft tissues. 
Stage 3 is characterized by extreme aggressiveness; 
the tumor is large in volume, destroying the bone and 
invading the surrounding tissues(7,8); as presented in 
the case reported here. The highest rate of recurrence 
is observed in tumors that are in this phase(7,8).
Histomorphological aspects
In its morphological aspect, GCT of the bone is 
solid, large, brown in color, with yellow areas of 
necrosis and dark red areas of hemorrhage. In cases 
with slower evolution, there are areas of whitish, star-
shaped fibrosis, with firm consistency at the core(14). 
Histologically, the neoplasic tissue is highly vascula-
rized, consisting of stroma with oval or fusiform cells, 
and numerous multinucleated giant cells, the nuclei of 
which are identical to those of the stroma cell(14). The-
re is little or no intercellular substrate, except for some 
collagen fibers. Mitotic figures may be numerous, but 
without abnormalities(7).
Differential diagnosis
Differential diagnosis should be performed with 
tumors that contain giant cells, like aneurismal bone 
cyst, giant cell reparative granuloma and brown tumor 
of hyperparathyroidism. These pathologies present a 
similar radiological pattern. Through the histologi-
cal findings, differentiation is possible, except with 
brown tumor of hypoparathyroidism, which requires 
biochemical studies for its diagnostic definition(7,8,11). 
Metastatic disease and multiple myeloma can also
be included(3).
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The treatment of GCT is surgical(1,4,5,10). The con-
duct should be well-planned and individualized, due to 
the unpredictable nature of the neoplasia in terms of its 
local prognosis(4). The greatest challenge is due to the 
aggressive local behavior of the tumor and its tendency 
to recur(6,8). Compared with GCT in proximal locations, 
tumors of the hand are presented in advanced stages 
with greater bone destruction and extension for diaphy-
sis, which complicates the treatment. The objective of 
the treatment in the hands is to achieve local control of 
the tumor and avoid recurrences, preserve the functions 
of the hand, and maintain a good esthetic standard(3,10). 
The types of treatment described in the literature are: 
curettage, curettage with bone graft, radiotherapy, am-
putation and resection with reconstruction(5). Curetta-
ge, whether in isolation or associated with bone graft, 
is the most common form of treatment, but it presents 
a rate of recurrence of around 90%(2,8). Curettage is 
not, therefore, the ideal intervention. Radiotherapy 
should also not be used as the primary procedure as 
it is associated with malignant transformation. Am-
putation, although it reduces the recurrence rates, is 
esthetically disfiguring and causes loss of functionality 
of the limb(2,5). In the present case, this procedure was 
carried out in order to prevent recurrence, due to the 
clinical condition presented. Resection with recons-
truction of the articulation of the proximal phalanx 
with the metacarpus can be carried out with a bone 
graft, prosthesis or with polymethylacrilate, which 
re-establishes the structural and functional integrity 
of the metacarpophalangeal joint(2,5). These last two 
forms of treatment are considered the treatments of 
choice in stage 3 lesions of the hand, where there is 
invasion of the surrounding soft tissues(8).
Prognosis
The rate of recurrence with the appropriate 
surgical technique is approximately 5% to 10%(1,7) 
and the majority occur around 12 to 18 months after 
the therapy(7). There is a study that reports a peak of 
recurrence three years after surgery(1). In the hands, 
the recurrence rate is higher(8,11), approximately 
70%(11). A literature review indicates that patients with 
recurrence should be carefully monitored due to the 
higher malignant potential of the recurrent disease, 
and the higher propensity to metastasis(3). Thus, due 
to the small, but definite risk of pulmonary metastasis, 
clinical follow-up and imaging exams are necessary for 
the rest of the patient’s life(15).
Pulmonary metastasis
The development of pulmonary metastasis is rare, 
its incidence varying between studies from 2% to 
6%(7,16). In the series of Bertoni et al(15) involving 327 
cases of GCT of the bone, only six presented pulmo-
nary metastasis. They generally occur in the first years 
after discovery of the primary bone tumor, at around 
3.5 years, on average(16). In relation to the surgical 
procedure, the appearance of pulmonary metastasis 
presented an interval of 17 to 40 months, according 
to a study by Athanasian et al(17), and 16.4 months in 
the series of Bertoni et al(15). The progression is gene-
rally slow(7). The increased incidence of pulmonary 
metastasis is associated with the location of the pri-
mary tumor in the distal radius, sacrum and hands, 
stage 3 lesions, aggressive local behavior, and multi-
ple recurrences, characteristics of the tumor(3,7,10). The 
clinical presentation (age, sex and tumor location) of 
GCT with pulmonary metastasis is similar to that of 
GCT without metastasis(15). The majority of pulmonary 
lesions are asymptomatic, and are incidentally detected 
during follow-up of the tumor. However, some patients 
present pulmonary symptoms before the discovery of 
the primary tumor(16). Regular chest x-ray and CT are 
therefore recommended(16). The histomorphological 
findings of the pulmonary metastatic nodules present 
the same benign morphology as the primary tumor in 
terms of cellularity, abundance of osteoid, anaplasia 
and mitotic aspects(7,16,18).
In the search for metastasis, the x-ray shows no-
dules of homogenous opacity, occasionally with peri-
pheral calcification. Most of the nodules occur in the 
basal and peripheral regions of the lungs. CT is the 
most sensitive method and can help determine more 
accurately the number of lesions and whether there is 
mediastinal involvement. It is extremely important in 
the surgical planning for removal of the metastases(16).
In cases of pulmonary metastasis, some tumors 
regress spontaneously, while others require surgical 
treatment. Resection of the pulmonary implants, whether 
by metastectomy, general resection or lobectomy, not 
only prevents extension of the lesion with progressive 
pulmonary dysfunction and confirms the diagnosis, but 
it may be a determining factor for the cure, without 
the need for additional treatment(15,16,18). Lesions that 
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are inaccessible to surgical treatment, rapidly recurring 
lesions, lesions with incomplete resection, or multiple 
lesions may respond to chemotherapy, including 
Interferon. High doses of Cisplatin, Cyclophosphamide, 
Methotrexate and Doxorubicin can prolong the disease-
free time. The response is variable. Many patients die 
from the side effects of chemotherapy, such as secondary 
sepsis due to agranulocytosis(7,15,16). Interferon alpha-2 
is a therapeutic option due to its antiangiogenic action, 
which results in a major reduction in tumor size(4). 
Radiotherapy may also be used in these situations, despite 
the risks of malignant sarcomatous transformation(15,16). 
This possibility of sending metastases is still a source of 
confusion for many authors, who start to consider GCT 
and treat it like a high malignity neoplasm. Commonly, 
descriptions of chemotherapy and even radiotherapy 
treatment are seen, in cases considered as malignization 
of a GCT. Benign histological analysis of the pulmonary 
nodule corroborates the affirmation that there is no 
malignant transformation of the GCT(19), therefore, 
these two last therapies are little used, as a series of 
studies describes that the absence of treatment of the 
pulmonary metastasis from the GCT of bone does not 
reduce long-term survival(15,16,18).
Follow-up
Due to the high incidence of local recurrence and 
the risk of pulmonary metastasis, it is extremely
important to closely monitor these patients(7).
Follow-up after treatment should initially be done 
every three to four months and should include phy-
sical and x-ray tests on the affected bone. This will 
enable any recurrence to be detected at an early stage. 
CT or MRI are useful for clarifying a suspected recur-
rence. After two to three years, the follow-up should 
be every six months, and then annually after five 
years of treatment. Chest x-ray should be requested 
in each follow-up visit due to the risk of pulmonary 
metastasis. Chest CT can be performed on diagnosis 
to check for early signs of pulmonary metastasis since 
CT is more sensitive than x-ray. Subsequently, in the 
absence of lesions, the patient is followed-up with 
x-ray at the above-mentioned intervals(7).
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GCT in the hand is a rare, benign, but locally 
aggressive entity. It evolves earlier than GCT in other 
locations. It is oligosymptomatic, with prevalence of 
pain and increased volume. It mainly affects young 
women, who are more subject to pulmonary metastasis. 
The diagnosis is based on the clinical, radiological and 
histopathological aspects. The treatment is surgical, but 
there is no consensus in the literature. Cases should be 
assessed individually to ensure safe intervention, seeking 
to prevent recurrences and functional limitations.
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